Stockscreener 앱 받기
2.215
3.71%
-0.075
Compass Therapeutics Inc 주식(CMPX)의 최신 뉴스
Compass Showcases Promising Tovecimig Data, Eyes Commercialization - TipRanks
Compass updates corporate presentation, reports positive Phase 2/3 COMPANION-002 BTC data and plans BLA engagement - TradingView
Compass Therapeutics (NASDAQ: CMPX) targets BLA after biliary tract cancer trial success - Stock Titan
CMPX Stock Has Retail Buzzing Ahead Of High-Stakes Cancer Drug Trial Update - Stocktwits
Enterprise value to revenue forward of Compass Therapeutics, Inc. – NASDAQ:CMPX - TradingView
Price to sales forward of Compass Therapeutics, Inc. – NASDAQ:CMPX - TradingView
$Compass Therapeutics (CMPX.US)$ - Moomoo
Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 3000 Growth Benchmark - marketscreener.com
Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Compass Therapeutics Inc. (CMPX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Compass Therapeutics (CMPX) Stock Forecast & Analyst Ratings - Moomoo
Compass Therapeutics, Inc. Actuals & Estimates (NASDAQ:CMPX) - TradingView
CMPX Forecast — Price Target — Prediction for 2027 - TradingView
Compass Therapeutics Inc. (CMPX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Compass Therapeutics Inc. (CMPX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Compass Therapeutics Adopts Second Amended and Restated Bylaws - TipRanks
Compass Therapeutics Inc. (CMPX) Institutional Confidence - TradingKey
Compass Therapeutics Inc. (CMPX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Compass Therapeutics Inc. (CMPX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Compass Therapeutics Inc. (CMPX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
How Compass Therapeutics (CMPX) Is Moving Tovecimig Toward a Potential Biliary Tract Cancer Filing - Insider Monkey
Compass Therapeutics Inc. (CMPX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
5 Small Cap Stocks with Potential to Rise 1000 Percent - Insider Monkey
Compass Therapeutics eyes FDA path after Tovecimig trial win - MSN
Compass Therapeutics Shareholders Back Directors, Pay, Auditor Oversight - The Globe and Mail
Compass Therapeutics (NASDAQ: CMPX) investors back board, auditor and pay in 2026 votes - Stock Titan
CMPX: Lead oncology asset tovecimig nears FDA filing after strong BTC trial results; multiple catalysts ahead - TradingView
Compass Therapeutics, Inc. (CMPX) Latest Stock News & Headlines - Yahoo Finance
Compass Therapeutics Eyes FDA Path After Tovecimig Trial Win - MarketBeat
CMPX News | COMPASS THERAPEUTICS INC (NASDAQ:CMPX) - ChartMill
Citizens reiterates Compass Therapeutics stock rating on ASCO data By Investing.com - Investing.com Nigeria
Citizens reiterates Compass Therapeutics stock rating on ASCO data - Investing.com
CMPX Stock Chart | COMPASS THERAPEUTICS INC (NASDAQ:CMPX) - ChartMill
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Compass Therapeutics (CMPX) and Tenax Therapeutics (TENX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Emergent Biosolutions (EBS) and Compass Therapeutics (CMPX) - The Globe and Mail
Piper Sandler Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Cuts Target Price to $4 - Moomoo
Stifel reiterates Compass Therapeutics stock rating on ASCO data By Investing.com - Investing.com Canada
Number of shareholders of Compass Therapeutics, Inc. – NASDAQ:CMPX - TradingView
CMPX Q1 2026 Earnings: Narrow EPS Beat Drives Positive Stock ReactionTrough Earnings Signal - thelegaladvocate.com
Compass Therapeutics to Participate in Upcoming June Investor Events - Investing News Network
Analysts Are Bullish on These Healthcare Stocks: Fortrea Holdings Inc. (FTRE), Cullinan Management (CGEM) - The Globe and Mail
CMPXCompass Therapeutics Inc Stock Price and Quote - Finviz
Compass Therapeutics (CMPX) Breaks Above Support: What’s Driving the 4.6% MoveStrangle Setup - newsline.com
CMPX Q1 2026 Earnings: Narrowed Loss Beats Estimates, Stock Surges 7.25%Forward Guidance Trends - newsline.com
CCORF Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Compass Therapeutics reports phase 1 data for CTX-8371 By Investing.com - Investing.com South Africa
Compass Therapeutics reports phase 1 data for CTX-8371 - Investing.com UK
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting - Investing News Network
Compass Therapeutics Announces Promising Phase 1 Results for CTX-8371, Innovative Dual Checkpoint Blocker in Advanced Malignancies - Quiver Quantitative
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc.CMPX - PR Newswire
1.95%
0.07%
자본화:
|
볼륨(24시간):